Electromed Inc. (ELMD)
AMEX AMEX Primary 
Electromed: Some Short Term Gain But I Fear Long Term Pain
Electromed (ELMD) has delivered strong revenue growth and margin improvement, but faces a highly competitive, fragmented market for its SmartVest product. ELMD lacks a durable moat, with rivals like Tactile Medical and Baxter showing stronger brand recognition, technological advantages, and higher recent growth rates. Scientific evidence questions the comparative efficacy of HFCWO versus alternative airway clearance therapies, undermining the long-term growth thesis for SmartVest.
3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes
ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.
Here is Why Growth Investors Should Buy Electromed (ELMD) Now
Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.
Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago.
5 Highly Efficient Stocks That Stand Out on Key Profitability Ratios
United Natural Foods leads a screen of five efficient stocks that beat peers on key ratios, highlighting names investors may consider for stronger returns.
3 Reasons Why Growth Investors Shouldn't Overlook Electromed (ELMD)
Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts See a 36.98% Upside in Electromed (ELMD): Can the Stock Really Move This High?
The consensus price target hints at a 37% upside potential for Electromed (ELMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Best Momentum Stock to Buy for Nov. 17th
ROKU, NRIM and ELMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 17, 2025.
Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Electromed (ELMD) could produce exceptional returns because of its solid growth attributes.
Electromed (ELMD) Upgraded to Buy: Here's Why
Electromed (ELMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Electromed (ELMD) Could Surge 39.17%: Read This Before Placing a Bet
The consensus price target hints at a 39.2% upside potential for Electromed (ELMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
